Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the ...
Morphological profiling allows accurate identification of cell types in dense iPSC-derived cultures, allowing its use for quality control and differentiation monitoring.
Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor ...
Scientists have adapted a sensing platform to detect and even measure chemicals at low enough concentrations to have use outside the lab. The system, which is 10 times more sensitive than previous ...
(Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced key expected 2025 milestones across its ...
Mavorixafor is a selective CXCR4 receptor antagonist approved in the U.S. and marketed by X4 as XOLREMDI®, an oral, once-daily treatment for patients 12 years of age and older with WHIM ...